Ramipril in Pediatric Patients on Hemodialysis

• Status: Completed
• Trial end date: 2020-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to evaluate the effect of Ramipril in pediatric patients on regular hemodilaysis

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Ramipril

Criteria

Inclusion Criteria:

• Patients < 16 years old

• Patients who have been on regular HD for 6 months or longer

• Hypertension at enrollment

Exclusion Criteria:

• History of active connective tissue disease

• Acute infection within 1 month prior to the study

• Advanced liver disease

• Gastrointestinal dysfunction requiring parental nutrition or active malignancy

• Use of medications such as immunosuppressive drugs within 1 month prior to the study

• Use of anti-inflammatory medications

• Use of vitamin E at a dose higher than 60 IU per day or vitamin C higher than 500 mg per day

• History of myocardial infarction or cerebrovascular event within 3 months prior to the study

• History of ACE inhibitor-associated angioedema

• Inability to discontinue ACE inhibitors or ARBs